Ultragenyx Sells Priority Review Voucher for $210 Million

“Benzinga reports Ultragenyx, ticker R-A-R-E, agreed to sell a rare pediatric disease priority review voucher for two hundred ten million dollars.” — Chip Darnell, on air

On air: Chip Darnell on Pre-Market Pixels
Published 8:35 AM ET, Wednesday, October 7, 2026

At a glance

First reported by Benzinga: “Ultragenyx Pharmaceutical Inks $210M Deal To Sell Rare Pediatric Disease Priority Review Voucher”.
Covered on BBN on Wednesday, October 7, 2026, at 8:35 AM ET on Pre-Market Pixels, by Chip Darnell.

The real story

The reporting behind this segment. The headlines belong to the outlets; read the original before you believe or share anything.

BenzingaUltragenyx Pharmaceutical Inks $210M Deal To Sell Rare Pediatric Disease Priority Review Voucher

What BBN said about it

Chip Darnell · U.S. News AnchorBenzinga reports Ultragenyx, ticker R-A-R-E, agreed to sell a rare pediatric disease priority review voucher for two hundred ten million dollars.
Chip Darnell · U.S. News AnchorJoining us from his bunker is prepper Gunnar Fallowfield.
Gunnar FallowfieldChip, thanks. A voucher is paper that jumps the line. I have been saying for years the line is the whole problem.
Chip Darnell · U.S. News AnchorUltragenyx gets cash for clinical development. Gunnar, does a two hundred ten million dollar sale prove anything to you?
Gunnar FallowfieldIt proves the end is near. Even a coupon now costs more than my entire bunker, and my bunker has a moat. A small moat.
Chip Darnell · U.S. News AnchorGunnar, a small moat sounds like a puddle. Is the puddle part of your plan?
Gunnar FallowfieldIt is a strategic puddle. Dale visited last spring, cried happy tears, and left his tea. I have been guarding it ever since.
Chip Darnell · U.S. News AnchorDale's tea is now a hostage situation. Gunnar, what is in your pantry besides fear?
Gunnar FallowfieldFour thousand cans of pudding and one very judgmental goose. Chip, we will have to leave it there, the goose is hissing at the camera.